Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with prostate cancer - EORTC QLQ-PR25.
OBJECTIVE
We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer QLQ-PR25 when applied to Korean prostate cancer (PC) patients.


METHODS
A total of 172 patients who underwent curative radical prostatectomy (RP) with or without adjuvant androgen deprivation therapy were asked to complete the Korean version of the EORTC QLQ-C30 and PR25 questionnaires 3 times (before and 3 and 6 months after RP). Psychometric evaluation of the questionnaire was conducted.


RESULTS
Multitrait scaling analysis showed satisfactory construct validity in most scales except for bowel symptoms and hormonal treatment-related symptoms. Internal consistency tested by Cronbach's α coefficient met the 0.70 criterion for the urinary symptom, sexual activity and sexual functioning scales at the all 3 time points. Known-group comparison analyses showed better quality-of-life (QOL) scores in patients with higher performance status, and higher hormonal treatment-related symptom scores in patients on hormonal treatment. Responsiveness to changes was in line with clinical implications over time after RP.


CONCLUSIONS
Our results show that the EORTC QLQ-PR25 questionnaire has adequate levels in cross-cultural validity. The Korean version of the EORTC QLQ-PR25 is a generally reliable and robust instrument for the assessment of various QOL aspects that can be self-administered to Korean PC patients undergoing RP.
Department of Urology, Eulji University Hospital, Daejeon, Korea.
Jinsung
J
Park
Dong Wook
DW
Shin
Seok Joong
SJ
Yun
Sung-Woo
SW
Park
Seong Soo
SS
Jeon
Cheol
C
Kwak
Tae Gyun
TG
Kwon
Hyung Jin
HJ
Kim
Hanjong
H
Ahn
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D003466:Cultural Characteristics; D007172:Erectile Dysfunction / Q000209:etiology; D005060:Europe; D005242:Fecal Incontinence / Q000209:etiology; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011468:Prostatectomy / Q000009:adverse effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000523:psychology / Q000601:surgery; D011594:Psychometrics; D011788:Quality of Life; D015203:Reproducibility of Results; D056910:Republic of Korea; D011795:Surveys and Questionnaires / Q000592:standards*; D014555:Urination Disorders / Q000209:etiology
D000726:Androgen Antagonists; D000970:Antineoplastic Agents